Elevance Health Shrinks to Grow Stronger: From Part D to Plan B?

Elevance Health (ELV) is strategically exiting certain underperforming Medicare Advantage markets and its standalone Part D segment, impacting approximately 150,000 members, to protect profitability and focus on higher-margin Medicare Advantage HMO and D-SNPs. This recalibration, driven by rising medical costs and reimbursement pressures, aligns with a broader industry trend, as evidenced by UnitedHealth (UNH) and Molina Healthcare (MOH) also trimming 2025 EPS forecasts and withdrawing from MA markets. ELV has revised its 2025 adjusted EPS outlook to $30 from a prior range of $34.15-$34.85 and faces a $375 million cost from a star ratings legal battle, contributing to a 14.6% year-to-date share decline and a Zacks Rank #4 (Sell).

Analysis

Elevance Health (ELV) is undertaking a significant strategic repositioning by exiting select Medicare Advantage markets and its entire standalone Part D business, a move designed to shield profitability from rising medical costs and reimbursement pressures. This action, impacting approximately 150,000 of its 2.3 million MA members, reflects a broader industry recalibration, as peers UnitedHealth (UNH) and Molina (MOH) have also announced material downward revisions to their 2025 earnings forecasts. The financial impact on Elevance is substantial, with its 2025 adjusted EPS guidance slashed to approximately $30 from a prior range of $34.15–$34.85, and consensus estimates now forecasting a 9.6% year-over-year earnings decline. This is compounded by a projected $375 million financial hit in 2025 from an unfavorable legal ruling on its star ratings. Despite these headwinds, which have driven the stock down 14.6% year-to-date, Elevance maintains a superior trailing 12-month return on capital of 10.4% versus the industry's 7.4%, suggesting strong operational discipline. The stock now trades at a forward P/E of 10.06, a notable discount to the industry average of 14.90, reflecting the market's pricing-in of near-term uncertainty against the company's long-term bet on higher-margin products.

Key Decisions for Investors

• Given the sharp downward revision of 2025 EPS guidance and the additional $375 million legal headwind, investors should anticipate continued near-term pressure on ELV's share price and factor in the 9.6% expected earnings decline.
• The strategic pivot to focus on higher-margin MA HMO and D-SNP plans is a defensive move; long-term investors should monitor for evidence that this focus successfully stabilizes margins and enrollment growth in subsequent quarters.
• While ELV's forward P/E of 10.06 presents a valuation discount to the industry, this must be weighed against systemic sector-wide risks, as demonstrated by similar guidance cuts from market leaders like UNH, suggesting the cost pressures are not isolated to Elevance.
• Consider holding existing positions but exercise caution on initiating new ones until there is greater clarity on the trajectory of medical cost trends and the execution of the company's strategic realignment.